Hi! I must revise my opinion: Unfortunately, BACE inhibitors have a very limited potential as disease-modifying drugs for AD, even if given in early (preclinical) disease states. On the one hand this is due to intolerable side effects which led to their failure in clinical studies. On the other hand, the amyloid beta pathology (as an isolated phenomenon) has been overestimated in its relevance for AD (so the same applies to vaccination strategies). Nevertheless, I am optimistic that novel strategies targeting tau pathology or network nodes where amyloid beta and tau pathways interact may result in a disease-modifying treatment in a few years. This treatment will have to be initiated in early disease stages, before neuronal loss can no longer be compensated, so research on early diagnosis is of extreme importance!